Urology
Volume 57, Issue 4, Supplement 1 , Pages 86-89 , April 2001

Other novel agents: Rationale and current status as chemopreventive agents

  • Anthony W Tolcher

      Affiliations

    • Institute for Drug Development, Cancer Therapy and Research Center, San Antonio, Texas, USA (AWT)
    • Corresponding Author InformationReprint requests: Anthony W. Tolcher, MD, Institute for Drug Development, Cancer Therapy and Research Center, 8122 Datapoint Drive, Suite 250, San Antonio, TX 78229
    • ,
  • Ann Kennedy

      Affiliations

    • University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, USA (AK)
    • ,
  • Robert J Padley

      Affiliations

    • Abbott Laboratories, Abbott Park, Illinois, USA (RJP)
    • ,
  • Noreen Majeed

      Affiliations

    • McGill University, Montreal, Quebec, Canada (NM, MP)
    • ,
  • Michael Pollak

      Affiliations

    • McGill University, Montreal, Quebec, Canada (NM, MP)
    • ,
  • Philip W Kantoff

      Affiliations

    • Dana-Farber Cancer Institute, Boston, Massachusetts, USA (PWK)

References 

  1. Kennedy AR. The Bowman-Birk inhibitor from soybeans as an anticarcinogenic agent. Am J Clin Nutr. 1998;68:1406S–1412S
  2. Kennedy AR. Chemopreventive agents (protease inhibitors). Pharmacol Ther. 1998;78:167–209
  3. Ware JH, Wan XS, Kennedy AR. Bowman-Birk inhibitor suppresses production of superoxide anion radicals in differentiated HL-60 cells. Nutr Cancer. 1999;33:174–177
  4. St. Clair WH, Billings PC, Carew JA, et al.  Suppression of dimethylhydrazine-induced carcinogenesis in mice by dietary addition of the Bowman-Birk protease inhibitor. Cancer Res. 1990;50:580–586
  5. Kennedy AR, Szuhaj BF, Newberne PM, et al.  Preparation and production of a cancer chemopreventive agent, Bowman-Birk inhibitor concentrate. Nutr Cancer. 1993;19:281–302
  6. Yavelow J, Collins M, Birk Y, et al.  Nanomolar concentrations of Bowman-Birk soybean protease inhibitor suppress x-ray induced transformation in vitro. Proc Natl Acad Sci USA. 1985;82:5395–5399
  7. Billings PC, St. Clair WH, Maki PA, et al.  Distribution of the Bowman Birk protease inhibitor in mice following oral administration. Cancer Lett. 1992;62:191–197
  8. Nelson JB, Chan-Tack K, Hedican SP, et al.  Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. Cancer Res. 1996;56:663–668
  9. Shichiri M, Hirata Y, Nakajima T, et al.  Endothelin-1 is an autocrine/paracrine growth factor for human cancer cell lines. J Clin Invest. 1991;87:1867–1871
  10. Battistini B, Chailler P, D’Orleans-Juste P, et al.  Growth regulatory properties of endothelins. Peptides. 1993;14:385–399
  11. Nelson JB, Lee WH, Nguyen SH, et al.  Methylation of the 5′ CpG island of the endothelin B receptor gene is common in human prostate cancer. Cancer Res. 1997;57:35–37
  12. Levin ER. Endothelins. N Engl J Med. 1995;333:356–363
  13. Benigni A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133–138
  14. Raffa RB, Schupsky JJ, Martinez RP, et al.  Endothelin-1-induced nociception. Life Sci. 1991;49:L61–L65
  15. Janus TJ, Samara E, Lanni C, et al.  ABT-627, endothelin-receptor antagonist, for advanced cancer (phase I and pharmacokinetic results). Proc Am Assoc Cancer Res. 1999;40:90;(Abstract 600)
  16. Tontonoz P, Singer S, Forman BM, et al.  Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci USA. 1997;94:237–241
  17. Tontonoz P, Nagy L, Alvarez JG, et al.  PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 1998;93:241–252
  18. Kubota T, Koshizuka K, Williamson EA, et al.  Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res. 1998;58:3344–3352
  19. Takahashi N, Okumura T, Motomura W, et al.  Activation of PPAR gamma inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett. 1999;455:135–139
  20. Sarraf P, Mueller E, Jones D, et al.  Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med. 1998;4:1046–1052[see comments]
  21. Elstner E, Muller C, Koshizuka K, et al.  Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci USA. 1998;95:8806–8811
  22. Saez E, Tontonoz P, Nelson MC, et al.  Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med. 1998;4:1058–1061
  23. Lefebvre AM, Chen I, Desreumaux P, et al.  Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med. 1998;4:1053–1057
  24. Neuschwander-Tetri BA, Isley WL, Oki JC, et al.  Troglitazone-induced hepatic failure leading to liver transplantation (a case report). Ann Intern Med. 1998;129:38–41[see comments]
  25. Baserga R, Resnicoff M, Dews M. The IGF-I receptor and cancer. Endocrine. 1997;7:99–102
  26. Nunn S, Gibson TB, Rajah R, et al.  Regulation of prostate cell growth by the insulin-like growth factor binding proteins and their proteases. Endocrine. 1997;7:115–118
  27. Kaplan PJ, Mohan S, Cohen P, et al.  The insulin-like growth factor axis and prostate cancer (lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model). Cancer Res. 1999;59:2203–2209
  28. Chan J, Stampfer M, Giovannucci E, et al.  Plasma insulin-like growth factor-I and prostate cancer risk (a prospective study). Science. 1998;279:563–565
  29. Wolk A, Mantzoros C, Andersson S-O, et al.  Insulin-like growth factor-I and prostate cancer risk (a population-based, case-control study). J Natl Cancer Inst. 1998;90:911–915
  30. Shaneyfelt T, Husein R, Bubley G, et al: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 18(4): 847–853, 2000.
  31. Pollak M, Beamer W, and Zhang JC: Insulin-like growth factors and prostate cancer. Cancer Metast Rev 17(4): 383–390, 1999.
  32. Pollak M. The potential role of somatostatin analogues in breast cancer treatment. Yale J Biol Med. 1998;70:1–5
  33. Trainer PJ, Drake WM, Katznelson L, et al: Treatment of acromegaly with the growth hormone-receptor antagonist Pegvisomant. N Engl J Med 342(16): 1171–1177, 2000.
  34. Lamharzi N, Schally AV, Koppan M, et al: Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc Natl Acad Sci USA 95(15): 8864–8868, 1998.
  35. Csernus VJ, Schally AV, Kiaris H, et al: Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc Natl Acad Sci USA 96(6): 3098–3103, 1999.
  36. Nickerson T, Pollak M. Bicalutimide (casodex)-induced prostate regression involves increased expression of genes encoding insulin-like growth factor binding proteins. Urology. 1999;54:1120–1125
  37. Nickerson T, Pollak M, and Huynh H: Castration-induced apoptosis in the rat ventral prostate is associated with increased expression of genes encoding insulin-like growth factor binding proteins 2,3,4 and 5. Endocrinology 139(2): 807–810, 1998.
  38. Huynh H, Seyam RM, and Brock GB: Reduction of ventral prostate weight by finasteride is associated with suppression of insulin-like growth factor I (IGF-I) and IGF-I receptor genes and with an increase in IGF binding protein 3. Cancer Res 58(2): 215–218, 1998.
  39. Nickerson T, and Huynh H: Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 160(2): 223–229, 1999.
  40. Huynh H, Pollak M, and Zhang JC: Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13(1): 137–143, 1998.
  41. Rozen F, Yang X, Huynh H, et al.  Antiproliferative effects of vitamin d-related compounds and insulin-like growth factor binding protein 5 accumulation. J Natl Cancer Inst. 1997;89:652–656

PII: S0090-4295(00)00948-1

Urology
Volume 57, Issue 4, Supplement 1 , Pages 86-89 , April 2001

Article Tools